Sarepta Therapeutics Faces Class Action Lawsuit Over Alleged Fraud

Investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have been alerted to a class action securities lawsuit filed by the law firm Levi & Korsinsky, LLP. The lawsuit claims that the company engaged in securities fraud affecting shareholders between June 22, 2023, and June 24, 2025.

The legal action seeks to recover losses on behalf of those adversely impacted by the alleged misconduct. According to the filed complaint, the defendants made misleading statements regarding ELEVIDYS, a prescription gene therapy designed to treat Duchenne muscular dystrophy. The lawsuit alleges that the company failed to disclose significant safety risks associated with the therapy. It further claims that the clinical trial protocols did not adequately identify severe side effects, which ultimately led to the halting of patient recruitment and dosing in ELEVIDYS trials.

The complaint details that this lack of transparency not only misled investors but also increased regulatory scrutiny, jeopardizing both current and future approvals for the therapy. As a result, shareholders were allegedly provided with overly optimistic assessments that lacked a reasonable basis.

If you suffered financial losses in Sarepta during the specified period, it is critical to note that you have until August 25, 2025, to request that the court appoint you as a lead plaintiff. Participation in the lawsuit does not require serving in this role, and investors may be entitled to compensation without any out-of-pocket costs.

Levi & Korsinsky, known for its expertise in complex securities litigation, has a history of securing substantial settlements for aggrieved shareholders. With a team of over 70 professionals, the firm has consistently ranked among the top securities litigation firms in the United States, according to the ISS Securities Class Action Services Top 50 Report.

For more information, investors are encouraged to contact Joseph E. Levi, Esq. at the firm via email or by telephone at (212) 363-7500.

This lawsuit represents a significant moment for Sarepta investors, as it highlights ongoing concerns regarding the safety and efficacy of its therapies. As the case unfolds, it may have far-reaching implications for the company and its shareholders.